Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Dianzani, Chiara ^a   Bellavista, Elena ^b   Liepe, Juliane ^c   Verderio, Claudia ^d,e   Martucci, Morena ^b   Santoro, Aurelia ^b   Chiocchetti, Annalisa ^f   Gigliotti, Casimiro Luca ^f   Boggio, Elena ^f   Ferrara, Benedetta ^a   Riganti, Loredana ^d   Keller, Christin ^g,h   Janek, Katharina ^g   Niewienda, Agathe ^g   Fenoglio, Chiara ⁱ   Sorosina, Melissa ^j   Cantello, Roberto ^f   Kloetzel, Peter M ^g,h   Stumpf, Michael P H ^c   Paul, Friedemann ^g,k   Ruprecht, Klemens ^g   Galimberti, Daniela ⁱ   Boneschi, Filippo Martinelli ^j   Comi, Cristoforo ^f   Dianzani, Umberto ^f   Mishto, Michele ^f,g,h   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CNR   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h BERLIN INSTITUTE OF HEALTH   (Germany)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; PROTEASOME;

AMINO ACID SEQUENCE; CHEMISTRY; CHEMOTAXIS; ENDOTHELIUM CELL; EXOSOME; EXTRACELLULAR SPACE; HUMAN; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MOLECULAR MODEL; MULTIPLE SCLEROSIS; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; CHEMOTAXIS; ENDOTHELIAL CELLS; EXTRACELLULAR SPACE; EXTRACELLULAR VESICLES; HUMANS; LYMPHOCYTES; MODELS, MOLECULAR; MULTIPLE SCLEROSIS; OSTEOPONTIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85014904136     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43718     Document Type: Article

References (42)

1. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 32, 257-281 (2014
2. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9, 440-447 (2009
3. Chowdhury S. A, Lin J, & Sadiq S. A. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 65, 232-235 (2008
4. Chiocchetti A, et al. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 163, 172-178 (2005
5. Comabella M, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158, 231-239 (2005
6. Hur E. M, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 8, 74-83 (2007
7. Shao Z, Morser J, & Leung L. L. Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-Terminal fragment. J Biol Chem 289, 27146-27158 (2014
8. Boggio E, et al. Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo. J Immunol Res 2016, 9345495, doi: 10.1155/2016/9345495 (2016
9. Groettrup M, Kirk C. J, & Basler M. Proteasomes in immune cells: more than peptide producers?. Nat Rev Immunol 10, 73-78 (2010
10. Liepe J, et al. Quantitative time-resolved analysis reveals intricate, differential regulation of standard- And immuno-proteasomes. Elife 4 (2015
11. Arciniega M, Beck P, Lange O. F, Groll M, & Huber R. Differential global structural changes in the core particle of yeast and mouse proteasome induced by ligand binding. Proc Natl Acad Sci USA 111, 9479-9484 (2014
12. Mishto M, et al. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol 44, 3508-3521 (2014
13. Sixt S. U, & Dahlmann B. Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta 1782, 817-823 (2008
14. Zoeger A, Blau M, Egerer K, Feist E, & Dahlmann B. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem 52, 2079-2086 (2006
15. Roth G. A, et al. Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35, 399-403 (2005
16. Bochmann I, et al. T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes. J Cell Mol Med 18, 59-68 (2014
17. Lai R. C, et al. Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. Int J Proteomics 2012, 971907 (2012
18. Henry L, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 58, 833-838 (2009
19. Henry L, et al. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Int J Cancer 133, 142-148 (2013
20. de Martino M, et al. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer 106, 904-908 (2012
21. Egerer K, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29, 2045-2052 (2002
22. Minagar A, et al. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b. Neurol Res 34, 611-618 (2012
23. Colombo E, Borgiani B, Verderio C, & Furlan R. Microvesicles: novel biomarkers for neurological disorders. Front Physiol 3, 63 (2012
24. Mueller O, et al. Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity. J Mol Neurosci 46, 509-515 (2011
25. Witwer K. W, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2 (2013
26. Liepe J, et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354-358 (2016
27. Ebstein F, et al. Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Sci Rep 6, 24032 (2016
28. Mishto M, et al. Driving Forces of Proteasome-catalyzed Peptide Splicing in Yeast and Humans. Mol Cell Proteomics 11, 1008-1023 (2012
29. Bellavista E, et al. Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. Autoimmune Dis 2014, 739705 (2014
30. Bellavista E, et al. Immunoproteasome in cancer and neuropathologies: a new therapeutic target?. Curr Pharm Des 19, 702-718 (2013
31. Kalim K. W, Basler M, Kirk C. J, & Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189, 4182-4193 (2012
32. Muchamuel T, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15, 781-787 (2009
33. Basler M, et al. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 6, 226-238 (2014
34. Mishto M, et al. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol (2014
35. Liepe J, et al. The 20S Proteasome Splicing Activity Discovered by SpliceMet. PLOS Computational Biology 6, e1000830 (2010
36. Yang J, et al. The I-TASSER Suite: protein structure and function prediction. Nat Methods 12, 7-8 (2015
37. Sivakumar S, & Niranjali Devaraj S. Tertiary structure prediction and identification of druggable pocket in the cancer biomarker -Osteopontin-c. J Diabetes Metab Disord 13, 13 (2014
38. Polman C. H, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69, 292-302 (2011
39. Quaglia M, et al. Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-Treated patients. Clin Rheumatol 33, 1263-1271 (2014
40. Heubner M, et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol 120, 233-238 (2011
41. Bianco F, et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. Embo J 28, 1043-1054 (2009
42. Mishto M, et al. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem 387, 417-429 (2006